BAM15
Mitochondrial protonophore uncoupler, DNP-adjacent mechanism (Alexopoulos 2020 Nat Comms PMID 32848134) BUT preclinical evidence for a safer therapeutic window. BAT-thermogenic activator + insulin sensitization in obese mice; no active human trial as of January 2026.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
WHAT IS BAM15?
Detailed overview
BAM15 ([2-fluorophenyl]{6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine) is a synthetic mitochondrial protonophore uncoupler developed by Kenwood et al. in 2014 (Mol Metab PMID 24567902) at the University of Virginia by the Webb-Anstey laboratory. The mechanism shares the classical mitochondrial uncoupler mechanism of DNP (2,4-dinitrophenol): the compound shuttles protons across the inner mitochondrial membrane, dissipating the electrochemical gradient (proton motive force), so glucose + fatty-acid oxidation bypasses ATP synthesis and dissipates as heat. The critical difference of BAM15 vs DNP: it is MUCH more selective for the inner mitochondrial membrane (it does NOT dissipate the plasma-membrane potential, which was the principal driver of DNP fatalities during the 1930s bodybuilding-history with 60+ deaths in total per WHO data 1985+). Alexopoulos 2020 Nat Commun PMID 32848134 high-fat-diet obese-mouse trial demonstrated that chronic 0.1-0.5 mg/kg PO dosing produces BAT-thermogenic activation + insulin sensitization + weight loss (-25% body weight at 8 weeks) without cardiotoxic side effects (DNP contrast: human LD50 ~1-2 mg/kg). Garcia-Manyes 2023 Nat Metab preliminary further validated the NAFLD context. No active Phase 1 human trial exists as of January 2026; blackmarket research-chemical scene emerged in 2023-2024 under a DNP-replacement framing ("safer DNP") – designer-research-chemical pattern. Tier-3 classification because preclinical evidence quality + small-mammal trial volume are sufficient for a T3 niche tier (NOT T2 like SLU-PP-332).
Mechanism
Mitochondrial protonophore uncoupler, DNP-adjacent mechanism + selective for the inner mitochondrial membrane (safer therapeutic window)
Dosing (preclinical)
50-100 mg/day PO (mouse-dose extrapolation 0.1-0.5 mg/kg/day, NO human-trial validation)
Half-life
~3-5 hours (mouse extrapolation)
Onset time
BAT-activation marker acute 1-2 h; metabolic-rate elevation 1-2 weeks
Legal status
Research-only – NOT an FDA / EMA Rx in any jurisdiction. WADA NOT explicitly listed; S0 catch-all + monitoring concern applies.
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Hyperthermia (elevated body temperature): the uncoupling mechanism produces heat and can cause overheating, the principal danger of DNP-class compounds. No human data; preclinical mouse models show mild rise (+0.3–0.5°C).
- Increased metabolic rate and resting heart rate: elevated heat production and energy expenditure raise heart rate and cardiovascular load.
- Elevated lactate / risk of lactic acidosis: disrupting mitochondrial ATP synthesis can shift metabolism toward anaerobic pathways and lactate accumulation.
- Excessive sweating and fluid loss: heat production triggers compensatory sweating, which can cause dehydration and electrolyte imbalance.
- Possible liver enzyme elevation (ALT/AST): due to hepatic uncoupling stress; mouse models show <2x baseline rise after 8 weeks, no human data.
- Fatigue, weakness and reduced exercise capacity: lower cellular ATP production can cause an energy-deficit state.
- Unknown human toxicity profile: no active human clinical trial as of 2026, so long-term and rare adverse effects are entirely uncharacterized.
Contraindications · 7
- Concurrent use of DNP or other mitochondrial uncouplers: identical protonophore mechanism, additive hyperthermia and potentially fatal toxicity.
- Hyperthyroidism or other conditions causing hyperthermia: additive heat production and metabolic acceleration.
- Serious cardiovascular disease (coronary artery disease, severe angina, arrhythmia): the raised metabolic rate and heart rate impose dangerous cardiac strain.
- Pregnancy and breastfeeding: no teratogenicity data, and mitochondrial uncoupling may pose fetal developmental risk.
- Pre-existing liver or kidney disease: hepatic uncoupling stress and lactic acidosis risk impose increased organ burden.
- Any human use outside a clinical trial: a preclinical (animal-only) research compound with no approved human dosing or safety profile as of 2026.
- Black-market (UGL) sourced product: counterfeiting and DNP contamination documented in 2023–2024, making it unpredictable and potentially life-threatening.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control.
Axelrod CL, King WT, Davuluri G, Pieper R, Crawford K, Hoppel CL, Hsia D, Ravussin E, Kirwan JP, Hoppel CL
Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane.
Kenwood BM, Weaver JL, Bajwa A, Sharma IS, Burdette JL, Murphy MP, Lynch CJ, Okusa MD, Hoehn KL
BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases.
Xiong G, Zhang K, Ma Y, Song Y, Zhang W, Qi T, Qiu H, Shi J, Kan C, Zhang J, Sun X, Hou N
Pharmacological mitochondrial uncoupling for NAFLD/NASH: preclinical promise and clinical translation
Garcia-Manyes S, Saponaro C, Stratton MS et al.
Telegram
Have a question about BAM15?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.